title: Novel therapeutic targets in advanced urothelial carcinoma.
abstract: Bladder cancer remains one of the most common and lethal diseases that cause approximately 150,000 deaths per year worldwide. Over the past two decades, the options currently available to patients with invasive disease remained essentially unchanged and no effective drugs have been approved in that time. Cisplatin-based combination chemotherapy remains the standard of care for first-line systemic treatment of metastatic urothelial carcinoma. However, the major advances in understanding the genetic background of urothelial tumors open up a new therapeutic area. Here, we summarize the current state of development of targeted agents in urothelial cancer; with an emphasis on immune checkpoints inhibitors and FGFR targeted therapies that represent the most promising therapeutic approaches for invasive bladder cancer.
authors.affiliation: Department of Urology, Foch Hospital, Versailles-Saint-Quentin-en-Yvelines University, Suresnes, France; INSERM U981, Gustave Roussy Cancer Campus, Paris-South University, Villejuif, France.
authors.forename: Mathieu
authors.initials: M
authors.lastname: Rouanne
authors.affiliation: INSERM U981, Gustave Roussy Cancer Campus, Paris-South University, Villejuif, France; Department of Cancer Medicine, Gustave Roussy Cancer Campus, Paris-South University, Villejuif, France. Electronic address: yohann.loriot@gustaveroussy.fr.
authors.forename: Yohann
authors.initials: Y
authors.lastname: Loriot
authors.affiliation: Department of Urology, Foch Hospital, Versailles-Saint-Quentin-en-Yvelines University, Suresnes, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Lebret
authors.affiliation: INSERM U981, Gustave Roussy Cancer Campus, Paris-South University, Villejuif, France; Drug Development Department, Gustave Roussy Cancer Campus, Paris-South University, Villejuif, France.
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Soria
mesh_terms: D019496:Cancer Vaccines / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000628:therapy*; D002945:Cisplatin / Q000627:therapeutic use; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D058990:Molecular Targeted Therapy / Q000639:trends; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D035703:Therapies, Investigational / Q000639:trends*; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*; D014571:Urologic Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D019496:Cancer Vaccines; D011505:Protein-Tyrosine Kinases; D002945:Cisplatin
keywords: Anti-PD-1/anti-PD-L1; FGFR inhibitor; Immunotherapy; Targeted therapy; Urothelial bladder carcinoma